COVID-19: Regulatory implications for Europe & Asia in the life sciences & healthcare industry

COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located. This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and state use/compulsory licensing.

Australia Belgium China Czech Republic Denmark Finland France Germany Hong Kong Hungary Italy The Netherlands Poland Singapore Slovakia Spain Sweden UAE UK

 

Australia Belgium China Czech Republic Denmark France Finland Germany 

Hong Kong Hungary Italy Netherlands Poland Singapore Slovakia Spain Sweden 

UAE United Kingdom


Compare all countries by topic

Clinical Trials   Medical Devices   Public Procurement (All countries) Public Procurement (Europe only) 

State Use/Compulsory Licensing